Viralgen and Axovia Therapeutics are set to form a partnership to progress the development and manufacturing of an adeno-associated virus vector serotype 9 (AAV9)-based gene therapy for retinal dystrophy in individuals with Bardet-Biedl Syndrome (BBS) due to BBS1 gene mutations.
The collaboration seeks to prevent vision loss in BBS patients.
The investigational gene therapy utilises a codon-optimised BBS1 AAV9 vector tailored to slow down vision loss caused by genetic defects.
Viralgen will manufacture the therapy at its facility, employing its expertise in AAV and the Pro10 cell line and manufacturing platform.
Combined with Axovia’s gene therapy development knowledge, the company seeks swift delivery.
Axovia co-founder and chief scientific officer Dr Victor Hernandez stated: 鈥淎s Axovia advances its pipeline of potential therapies addressing the genetic causes of blindness towards the clinic, we want to ensure we have appropriately scaled AAV manufacturing to support this effort, and are very happy to have partnered with Viralgen as our CDMO [contract development and managing organisation].
US Tariffs are shifting - will you react or anticipate?
Don鈥檛 let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalData鈥淥ur lead programme, AXV-101, which is being developed to address retinal dystrophy associated with BBS, is expected to enter clinical development in mid-2025, and we believe this partnership will ensure fast and efficient development as we seek to advance this therapy toward patients as soon as possible.鈥�
BBS leads to multi-system impairments, including obesity and progressive retinal dystrophy.
Viralgen, established in 2017 as AskBio鈥檚 independently operated subsidiary, is part of the Bayer Group.
The company鈥檚 facilities in San Sebasti谩n, Spain, feature a commercial facility with three modules, each housing three current good manufacturing practices suites with capacities exceeding 2,000L.
Cell & Gene Therapy coverage on 色界吧 Technology is supported by听Cytiva.
Editorial听content is independently produced and follows the听听of journalistic integrity. Topic sponsors are not involved in the creation of听editorial听content.
